Author

Yijing Ren

Institution: Antengene Corporation Limited (China)

Observed institution: Antengene Corporation Limited (China)

ORCID: 0009-0004-8848-7630

Observed ORCID: 0009-0004-8848-7630

OpenAlex ID: A5032210639

ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al. · Cancer Research · 21

Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Table S6 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Data from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Table S3 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Table S4 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Supplementary Table S5 from ATG-101 Is a Tetravalent PD-L1×4-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1–Directed 4-1BB Activation

2024 · Hui Yuwen, Huajing Wang, et al.

Works count: 9

Citation count: 21

H-index: 1

I10-index: 1